Overview:
Treating patients with EGFR-mutated metastatic NSCLC is no longer one treatment decision. Classical mutations now carry a first-line choice between a third-generation EGFR tyrosine kinase inhibitor alone and two intensified regimens. Exon 20 insertions have an approved infused first-line standard and oral regimens with new phase 3 data, while atypical and compound variants are matched to agents largely on single-arm evidence. Each class presents its own decision tree, requiring careful consideration of clinical data and patient/disease characteristics.
The Medical Crossfire® format puts these unsettled decisions
before a faculty panel that takes positions and defends them with evidence.
This program will convene national thoracic oncology leaders, the clinicians
who set institutional practice and train others, and the livestream will carry
the debate to the greater thoracic oncology community.
Learning Objectives:
Upon
completion of this activity, participants will be able to:
- Evaluate phase 3 evidence for first-line TKI monotherapy, TKI-chemotherapy and bispecific antibody-TKI combinations to identify patients with classical EGFR-mutated metastatic NSCLC who benefit from intensification
- Compare approved and emerging oral TKI and bispecific antibody strategies for EGFR exon 20 insertion-mutated NSCLC across lines of therapy, including differences in dosing and toxicity
- Develop first-line treatment plans for atypical and compound EGFR mutations based on the structural class of the reported variant, CNS disease, and the strength of evidence
Target Audience:
This educational activity is directed toward medical oncologists, thoracic oncologists, pathologists, advanced practice providers, nurses, pharmacists, and other health care professionals involved in the care of patients with EGFR-mutant non-small cell lung cancer.

Zofia Piotrowska, MD, MHS
Associate Professor of Medicine
Harvard Medical School
Clinical Co-Director, MGB Thoracic Medical Oncology Program
Mass General Brigham Cancer Institute
Boston, MA
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’
Education Resource®, LLC is approved by the California Board of
Registered Nursing, Provider #16669, for 1.0 Contact Hour.

